July 01, 2025

Stem Cell Therapy Shows T1D Reversal Potential

A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant

June 10, 2025

Does Autism-Linked Cortical Noise Impair Sleep?

New research presented at SLEEP 2025 links increased auditory cortex excitability with poor sleep efficiency in children—especially those with autism spectrum disorder—offering insight into sensory-driven sleep disturbances.

Conexiant

April 25, 2025

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Dana-Farber

June 03, 2025

Phytosterols May Shield Against Diabetes, CVD

Large Harvard study shows higher phytosterol intake, particularly beta-sitosterol, reduces type 2 diabetes and cardiovascular disease risk by up to 9%.

Conexiant

May 30, 2025

Major Medical Societies Issue GLP-1 Nutrition Guidelines

New advisory addresses nutritional challenges and side effects for obesity treatment

Conexiant

January 13, 2025

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy

Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.”

Dana-Farber

May 06, 2025

Shorter Prostate Radiotherapy Proves Long-Term Match

Two-week radiation treatment for localized prostate cancer delivers equivalent 10-year outcomes to standard 8-week course in a clinical trial.

Conexiant